Showing 1421-1430 of 1601 results for "".
- NeoStrata® Launches SKIN ACTIVE Dermal Replenishmenthttps://practicaldermatology.com/news/neostrata-launches-skin-active-dermal-replenishment/2458980/NeoStrata Company, Inc., today announced the launch of SKIN ACTIVE Dermal Replenishment, an intense hydrator that delivers a powerful four-pronged anti-aging approach. Created to synergistically replenish optimal hydration levels and reverse signs of a
- Nextech Systems and Iagnosis Showcase New Partnershiphttps://practicaldermatology.com/news/nextech-systems-and-iagnosis-showcase-new-partnership/2458982/Nextech, a leading provider of specialty-focused healthcare technology solutions for physician practices, announced an exclusive partnership with Iagnosis, a leading telemedicine provider of online dermatology solutions. Iagnosis provides a teledermatolog
- Syneron Candela Launches "Changing Lives" Program At AADhttps://practicaldermatology.com/news/syneron-candela-launches-changing-lives-program-at-aad/2458985/Syneron Medical Ltd. is introducing the Changing Lives Program, a corporate wide initiative that the company says leverages its life-changing technologies with life-changing causes. Launching at the annual American Academy of Dermatology (AAD) meeting in San Francisco on March 21, Changing Lives&
- Envy Medical Unveils SilkPeel3https://practicaldermatology.com/news/envy-medical-unveils-silkpeel3/2458990/Envy Medical, Inc. will launch its SilkPeel3, the next generation of its Advanced Dermalinfusion Technology, at the Annual Meeting of the American Academy of Dermatology on March 20-24 in San Francisco at Booth 312. Unveiled originally in 2005, SilkPeel is celebrating its 10th
- Three New CeraVe Baby Products Awarded National Eczema Association Seal of Acceptancehttps://practicaldermatology.com/news/three-new-cerave-baby-products-awarded-national-eczema-association-seal-of-acceptance/2458995/Valeant Pharmaceuticals North America LLC is pleased to announce today that all three products in its newest product line, CeraVe® Baby, have been awarded the National Eczema Association (NEA) Seal of Acceptance™, which maintains rigorous standards for approval. Products include Ce
- L'Oreal International Extends Deadline for Social Responsibility in Dermatology Awardshttps://practicaldermatology.com/news/loreal-international-extends-deadline-for-social-responsibility-in-dermatology-awards/2458996/L’Oréal announced today the extension of the closing date of its International Awards for Social Responsibility in Dermatology to April 15th 2015. Patients with dermatological conditions may frequently face discrimination and feel socially excluded,
- Cosmederm Bioscience Introduces Steve Massah as New Chief Operating Officerhttps://practicaldermatology.com/news/cosmederm-bioscience-introduces-steve-massah-as-new-chief-operating-officer/2459004/Cosmederm Bioscience has hired Steve Massah as its new Chief Operating Officer. As COO, Massah will provide strategic and tactical leadership, and management of manufacturing, product development, quality and product shipment and logistics. His work will ensure compliance with all government regu
- Can-Fite Receives Notice of Allowance in US for Psoriasis Patenthttps://practicaldermatology.com/news/can-fite-receives-notice-of-allowance-in-us-for-psoriasis-patent/2459005/Can-Fite BioPharma Ltd. received a Notice of Allowance from the US Patent and Trademark Office for CF101 in the treatment of psoriasis. The patent, which is expected to be issued in the next few weeks, is titled, "Pharmaceutical Composition Comprising A3 Adenosine Receptor Agonist (IB-M
- Halozyme Appoints Jean-Pierre Bizzari, MD to Board Of Directorshttps://practicaldermatology.com/news/halozyme-appoints-jean-pierre-bizzari-md-to-board-of-directors/2459021/Halozyme Therapeutics, Inc. appointed of Jean-Pierre Bizzari, MD to its Board of Directors. Dr. Bizzari brings extensive experience in oncology drug development. "I am delighted to welcome Jean-Pierre to our Board of Directors," said Dr. Helen Torley, President and Chief Executi
- FDA Grants Soligenix Fast Track Designation for SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphomahttps://practicaldermatology.com/news/fda-grants-soligenix-fast-track-designation-for-sgx301-for-first-line-treatment-of-cutaneous-t-cell-lymphoma/2459030/Soligenix, Inc.’s SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) received "fast track" designation from the FDA. Fast track is a designation that the FDA reserves for a drug intended to treat a serious or life-thre